Pharma channel feed

Acor­da shares tank as ap­peals court re­fus­es in­junc­tion against cheap Ampyra knock­offs

7 years ago

Za­vante CEO sells his late-stage an­tibi­ot­ic biotech to Nabri­va — grab­bing the helm in the deal

7 years ago
People

Bio­gen climbs high­er on Spin­raza sales; inks deal for two new neu­ro­mus­cu­lar drugs

7 years ago

Fol­low­ing some clean sweeps in PhI­II, Ab­b­Vie gets an FDA OK on its top-10 block­buster prospect Orilis­sa

7 years ago

As Ei­sai, Bio­gen plot a course to ac­cel­er­at­ed ap­provals for Alzheimer’s drug, a mob of skep­tics are wait­ing to de­ci­pher hard num­bers

7 years ago
R&D

GSK gains a PRV along­side FDA ap­proval for re­cur­ring malar­ia treat­ment

7 years ago

FDA pos­es some tough ques­tions for GSK’s pitch to gain an ap­proval for Nu­cala in COPD

7 years ago

Lil­ly inks R&D deal with An­i­ma, pay­ing $44M in re­search fund­ing and up­front pay­ments

7 years ago
R&D

Agios scores its sec­ond new drug ap­proval, ivosi­denib heads to the AML mar­ket

7 years ago

So­bi signs $450M deal for rare dis­ease drug ema­palum­ab, boost­ing its in­flam­ma­tion, I/O pipeline

7 years ago

Roche has tak­en the Trump pledge, join­ing Pfiz­er, No­var­tis and Mer­ck in promis­ing to hold the line on drug prices

7 years ago

PureTech grabs up to $36M from Roche to re­search milk-in­spired de­liv­ery plat­form

7 years ago

In an­oth­er win for Trump, Mer­ck takes the drug pric­ing pledge. Its cuts are a joke, but is this an in­dus­try tip­ping point?

7 years ago

FDA’s CDER un­veils de­tails of re­or­ga­ni­za­tion

7 years ago

The Shkre­li rule? FDA is ex­plor­ing whether se­lect­ed reim­por­ta­tion could crip­ple the drug prof­i­teers

7 years ago

Go­ing deep­er in­to the ezce­ma game, No­var­tis or­ches­trates $1.1B deal for a Mor­phoSys/Gala­pa­gos drug

7 years ago
R&D

UK votes to stay in the EMA post-Brex­it

7 years ago

J&J joins block­buster HIV com­bo race with new­ly ap­proved 4-in-1 pill

7 years ago

By the num­bers: Se­ries A rounds are bust­ing out, plat­forms are in, M&A is down, val­u­a­tions surge and 2018 looks wicked big

7 years ago
Financing
Deals

No­var­tis CEO Vas Narasimhan hits the brakes on US drug price hikes -- right af­ter tap­ping the gas

7 years ago

An­ti­fun­gal out, can­cer in: Rev­o­lu­tion scores $500M Sanofi deal on first on­col­o­gy pro­gram

7 years ago

An­oth­er stark warn­ing over CRISPR/Cas9’s po­ten­tial to do last­ing harm dents share prices

7 years ago

Phar­ma 'greed' emerges as a po­tent po­lit­i­cal is­sue in a rau­cous elec­tion year

7 years ago

Tak­ing on biode­fense threats, an­tibi­otics mak­er Spero inks $54M in gov­ern­ment deals

7 years ago
R&D
First page Previous page 296297298299300301302 Next page Last page
A service from the Financial Times